Novartis entered into an agreement to acquire Idenix Pharmaceuticals by acquiring 51% stake in Idenix, thereby substantially expanding its product portfolio in the field of antiviral drugs. The acquisition deal could be worth up to US$225 M. Following the acquisition the two companies would co-develop and co-commercialize Idenix’s antiviral drugs.